BECTON DICKINSON & CO BDX

BD delivered a strong Q1 FY25, exceeding financial goals with 9.6% reported revenue growth and 3.9% organic growth. The company achieved significant margin expansion, with adjusted gross margin up 370 basis points and adjusted operating margin up 340 basis points. This operational strength translated into 28% growth in adjusted diluted EPS to $3.43. BD also returned over $1 billion to shareholders, including $300 million in dividends and a $750 million accelerated share buyback.

BD announced its intent to separate its Biosciences and Diagnostic Solutions business, a decision stemming from a comprehensive portfolio evaluation initiated in early 2024. This strategic move is designed to enhance focus, drive growth through targeted capital deployment, and unlock significant value for both the new BD, which will be a pure-play MedTech company, and the separated entity, positioned as a pure-play leader in life science tools and diagnostics.

The new BD is envisioned as a $17.8 billion MedTech leader with global reach across a $70 billion+ addressable market, growing at approximately 5%. It will be organized into four operating segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The company expects an accelerating growth profile, attractive margins, and over 90% recurring revenue, with a concentrated focus on high-impact R&D and growth-accretive M&A to drive differentiated and durable growth rates.

The separated Biosciences and Diagnostic Solutions business is expected to be a leader in an attractive $22 billion+ addressable market, growing at mid- to high single digits. With FY24 revenues of $1.5 billion for Biosciences and $1.8 billion for Diagnostic Solutions, the combined entity is projected to have a highly attractive growth and margin profile, over 80% recurring revenue, and approximately 30% adjusted EBITDA margins. It will focus on accelerating its strong innovation pipeline in flow cytometry, molecular diagnostics, and microbiology.

BD continues to advance its innovation pipeline across segments. In BD Medical, a 510(k) was submitted for the BD Alaris Infusion System, enabling over-the-air software updates and including a new EtCO2 module. The company also received 510(k) clearance for the next-gen HemoSphere Alta Monitor and new Swan IQ and ForeSight IQ Smart Sensors. In BDI, EU approval was secured for Phasix resorbable mesh for incisional hernia prevention, and the first patients were enrolled in the GalaFLEX capsular contraction prevention clinical trial. Life Sciences is on track to launch the BD FACSDiscover Analyzer, A8, in H2 FY25 and is seeing accelerating sales momentum for its BD Onclarity HPV Assay.

BD is on track to exceed all financial targets set at its 2021 Analyst Day. The company expects to deliver a base organic revenue CAGR of 5.9% through 2025, surpassing the 5.5% target. Operating margins are projected to expand by 560 basis points to over 25%, exceeding the revised target of 540 basis points. Additionally, BD anticipates a 13.8% adjusted EPS CAGR, well above its double-digit target, demonstrating successful transformation into a faster-growing, more profitable organization.

The company is committed to exploring all separation options, including a Reverse Morris Trust, sale, or spin-off, to maximize shareholder value. Specifics on the separation plans are expected to be announced by the end of fiscal 2025, with the transaction targeted for completion in fiscal 2026. Management emphasized that the decision is based on portfolio strength and the opportunity to unlock value by creating two focused entities.